Cochrane Database Syst Rev
Amyloid-clearing Alzheimer’s drugs show little clinical payoff
Clinical Takeaway: For patients with mild cognitive impairment or mild Alzheimer’s dementia, amyloid‑beta monoclonal antibodies are unlikely to produce clinically meaningful cognitive or functional improvement and increase the risk of amyloid‑related imaging abnormalities.
Amyloid‑targeting antibodies are entering clinical practice worldwide, yet their benefits remain modest while risks and costs are substantial.
In a major Cochrane review published in April 2026, investigators analyzed 17 randomized controlled trials enrolling 20,342 people with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease. The trials evaluated seven amyloid‑beta–targeting monoclonal antibodies, including aducanumab, lecanemab, and donanemab, with follow‑up ranging from 12 months to more than two years.
Across studies, amyloid‑lowering therapies produced little to no difference in cognitive decline compared with placebo. At 18 months, the most consistently reported time point, effects on memory, global cognition, and dementia severity were rated as trivial and below accepted thresholds for minimal clinically important difference. Functional outcomes showed similarly limited gains, with changes in activities‑of‑daily‑living scores described as small at best.
The antibodies consistently reduced amyloid burden on brain imaging, but this biomarker improvement didn’t translate into meaningful clinical benefit. In contrast, harms were more apparent. Treatment increased the risk of amyloid‑related imaging abnormalities (ARIA), including brain edema and microbleeds, although most events were detected on MRI rather than through symptoms. Rates of serious adverse events and mortality were not higher than placebo.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Francesco Nonino, MD, PhD, noting a disconnect between amyloid clearance and outcomes patients actually experience.
The findings have generated debate within the Alzheimer’s community. Critics argue that pooling older, failed antibodies with newer agents risks obscuring modest but statistically significant benefits seen in individual phase 3 trials of lecanemab and donanemab, both of which have received regulatory approval in several regions, including the US. In a response from the UK Dementia Research Institute, researchers said combining heterogeneous drugs “turns therapeutic progress into statistical noise” and emphasized that anti‑amyloid antibodies are not a uniform class.
Others, while acknowledging the methodological concerns, agree with the review’s central message: biomarker change alone is not enough. Even commentators defending newer drugs concede that clinical effects are small and must be weighed against costs, monitoring burdens, and uncertainty around long‑term ARIA risk.
The review ultimately challenges the field to define clearer standards for meaningful benefit and to accelerate research beyond amyloid‑focused strategies.
Sources:
Nonino F, et al. (2026, April 16). Cochrane Database Syst Rev. Amyloid‑beta‑targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease
Wise J. (2026, April 16). BMJ. Alzheimer’s drugs targeting amyloid do not produce clinically meaningful effects, concludes Cochrane review
Burns C. (2026, April 16). The Pharmaceutical Journal. Amyloid‑targeting Alzheimer’s drugs ‘probably’ not effective
UK Dementia Research Institute. (2026, April 16). UK DRI responds to Cochrane review suggesting anti‑amyloid Alzheimer’s drugs show no clinically meaningful effect